A Phase 2 interventional study of Placebo for Sitagliptin 25 mg and Placebo for Sitagliptin 50 mg in Glucose Intolerance, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-01-18.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is being done to evaluate the safety, efficacy, and dose level of sitagliptin (MK-0431/ONO-5435) used once daily (qd) in Japanese participants with impaired glucose tolerance who have inadequate glycemic control using diet and exercise therapy.
793 studies on the registry are indexed under Glucose Intolerance; 115 are open to participants now.
This study's enrollment of 242 is above the median of 56 across 661 interventional studies indexed under Glucose Intolerance.
Browse Glucose Intolerance studies →Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will take one tablet of placebo for sitagliptin 25 mg and one tablet of placebo for sitagliptin 50 mg orally once daily for 8 weeks.
Drug: Placebo for Sitagliptin 25 mg · Drug: Placebo for Sitagliptin 50 mg
Participants will take one tablet of sitagliptin 25 mg and one tablet of placebo for sitagliptin 50 mg orally once daily for 8 weeks.
Drug: Placebo for Sitagliptin 50 mg · Drug: Sitagliptin 25 mg
Participants will take one tablet of sitagliptin 50 mg and one tablet of placebo for sitagliptin 25 mg orally once daily for 8 weeks.
Drug: Placebo for Sitagliptin 25 mg · Drug: Sitagliptin 50 mg
1 tablet orally once daily before breakfast for 8 weeks
1 tablet orally once daily before breakfast for 8 weeks
1 tablet orally once daily before breakfast for 8 weeks
Also known as: MK-0431/ONO-5435
1 tablet orally once daily before breakfast for 8 weeks
Also known as: MK-0431/ONO-5435
Percent Change From Baseline in Glucose Total Area Under the Concentration Curve 0 to 2 Hours (AUC 0-2 Hrs) for Meal Tolerance Test (MTT) at Week 8
Glucose total AUC 0-2 hours for MTT was measured at Baseline (Week 0) and at Week 8. After fasting for ≥10 hours, blood samples for glucose measurement were drawn at 0 minutes (at standard meal loading), 30 minutes, 60 minutes, 90 minutes, and 120 minutes. At Week 8, participants received study drug or placebo 30 minutes prior to consuming a standard meal.
Time frame: Baseline (Week 0) and Week 8
Percentage of Participants Who Experienced One or More Adverse Events (AEs)
An AE is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.
Time frame: Up to 10 weeks
Percentage of Participants Who Discontinued Treatment Due to an Adverse Event (AE)
An AE is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.
Time frame: Up to 8 weeks
Percent Change From Baseline in Glucose Total Area Under the Concentration Curve 0 to 2 Hours (AUC 0-2 Hrs) for 75-gram Oral Glucose Tolerance Test (OGTT) at Week 7
Glucose total AUC 0-2 hours for 75 g OGTT was measured at Baseline (Week -1) and at Week 7. After fasting for ≥10 hours, blood samples for glucose measurement were drawn at 0 minutes (at 75 g glucose loading), 30 minutes, 60 minutes, 90 minutes, and 120 minutes. At Week 7, participants received study drug or placebo 30 minutes prior to loading 75 g glucose solution.
Time frame: Baseline (Week -1) and Week 7
| Milestone | Placebo | Sitagliptin 25 mg | Sitagliptin 50 mg |
|---|---|---|---|
| Started | 83 | 82 | 77 |
| Treated | 82 | 82 | 77 |
| Completed | 79 | 79 | 76 |
| Not completed | 4 | 3 | 1 |
| Withdrew: Pre-treatment lab ae | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 1 | 1 |
Glucose total AUC 0-2 hours for MTT was measured at Baseline (Week 0) and at Week 8. After fasting for ≥10 hours, blood samples for glucose measurement were drawn at 0 minutes (at standard meal loading), 30 minutes, 60 minutes, 90 minutes, and 120 minutes. At Week 8, participants received study drug or placebo 30 minutes prior to consuming a standard meal.
| Percent change | Placebo | Sitagliptin 25 mg | Sitagliptin 50 mg |
|---|---|---|---|
| Percent Change From Baseline in Glucose Total Area Under the Concentration Curve 0 to 2 Hours (AUC 0-2 Hrs) for Meal Tolerance Test (MTT) at Week 8 | -2.42 (-4.48 to -0.31) | -9.52 (-11.43 to -7.57) | -11.49 (-13.40 to -9.55) |
Glucose total AUC 0-2 hours for 75 g OGTT was measured at Baseline (Week -1) and at Week 7. After fasting for ≥10 hours, blood samples for glucose measurement were drawn at 0 minutes (at 75 g glucose loading), 30 minutes, 60 minutes, 90 minutes, and 120 minutes. At Week 7, participants received study drug or placebo 30 minutes prior to loading 75 g glucose solution.
| Percent change | Placebo | Sitagliptin 25 mg | Sitagliptin 50 mg |
|---|---|---|---|
| Percent Change From Baseline in Glucose Total Area Under the Concentration Curve 0 to 2 Hours (AUC 0-2 Hrs) for 75-gram Oral Glucose Tolerance Test (OGTT) at Week 7 | -3.68 (-6.66 to -0.60) | -21.38 (-23.81 to -18.87) | -20.09 (-22.61 to -17.48) |
An AE is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.
| Percentage of participants | Placebo | Sitagliptin 25 mg | Sitagliptin 50 mg |
|---|---|---|---|
| Percentage of Participants Who Experienced One or More Adverse Events (AEs) | 30.9 | 34.1 | 41.0 |
An AE is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.
| Percentage of participants | Placebo | Sitagliptin 25 mg | Sitagliptin 50 mg |
|---|---|---|---|
| Percentage of Participants Who Discontinued Treatment Due to an Adverse Event (AE) | 0.0 | 0.0 | 0.0 |
Collected over Up to 10 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/81 (0%) | 0/81 (0%) | 13/81 (16%) |
| Sitagliptin 25 mg | 0/82 (0%) | 0/82 (0%) | 14/82 (17.1%) |
| Sitagliptin 50 mg | 0/78 (0%) | 0/78 (0%) | 11/78 (14.1%) |
| Event | Placebo | Sitagliptin 25 mg | Sitagliptin 50 mg |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 7/81 | 9/82 | 7/78 |
| HypoglycaemiaMetabolism and nutrition disorders | 7/81 | 5/82 | 4/78 |
| Age, Continuous(Years) | Placebo | Sitagliptin 25 mg | Sitagliptin 50 mg | Total |
|---|---|---|---|---|
| Mean | 61.9 ± 10.6 | 63.1 ± 9.5 | 61.9 ± 9.3 | 62.3 ± 9.8 |
| Sex: Female, Male(Participants) | Placebo | Sitagliptin 25 mg | Sitagliptin 50 mg | Total |
|---|---|---|---|---|
| Female | 35 | 38 | 32 | 105 |
| Male | 48 | 44 | 45 | 137 |
No study locations are listed for this record.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Aug 2011 to primary completion in Apr 2012, 7 months.
Results were first posted in Dec 2019, 7 years 8 months after primary completion.
Of 22 phase 2 interventional studies under Glucose Intolerance, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 99. This study's 7 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sitagliptin